西洛他唑对老年下肢动脉硬化闭塞症患者超敏C反应蛋白、血脂及基质金属蛋白酶-9的影响

目的探讨西洛他唑对老年下肢动脉硬化闭塞症患者超敏C反应蛋白(Hs-CRP)、血脂及基质金属蛋白酶9(MMP-9)的影响。方法选择老年下肢动脉硬化闭塞症患者60例,随机分为基本治疗组和西洛他唑组,同时以30例健康体检人员作为对照组。观察治疗后各组Hs-CRP、血脂及MMP-9的变化。结果治疗后基本治疗组血脂变化不明显,西洛他唑组总胆固醇(TC)水平明显下降,高密度脂蛋白胆固醇(HDL-C)显著上升。治疗后2组Hs-CRP、MMP-9水平均明显下降,西洛他唑组下降幅度大于基本治疗组。结论西洛他唑通过降低炎性因子浓度,调解血脂,降低Hs-CRP、MMP-9等途径改善下肢血管病变患者症状。

Effects of cilostazol on the highsensitive creactive protein, blood lipid and matrix metalloproteinase-9 in elderly patients with lower extremity arteriosclerosis obliterans

Objective To observe the effects of Cilostazol on the highsensitive creactive protein(Hs-CRP),blood lipid and matrix metalloproteinase-9 (MMP-9) in elderly patients with lower extremity arteriosclerosis obliterans. Methods Sixty aged patients with lower extremity arteriosclerosis obliterans were randomly assigned to conventional therapy group(group A) and Cilostazol group(group B).Thirty healthy people were selected as the normal group. Hs-CRP,blood lipid and MMP-9 in blood serum were measured be fore and after therapy. Results After therapy the level of blood lipid in blood serum of group A had not a marked change. But the level of high density lipoprotein of group B increased obviously.At the same time the level of Hs-CRP and MMP-9 decreased.The degree of decrease in group B was more significant than that in group A. Conclusions The therapy of Cilostazol can adjust blood lipid metabolism,decrease inflammatory factors and improve symptoms.